ramucirumab,pembrolizumab
merck,eli lilly
['ramucirumab', 'nsclc', 'lung', 'pembro', 'sclc', 'lung-map']
the combination of pembrolizumab plus ramucirumab resulted in better overall survival compared with the standard of care regimens despite similar response rates, according to results of a lung-map substudy presented at #asco22. #nsclc | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.